Wikipedia -WSS

Wikipedia

author：explore 2025-09-28 00:51:58 - browse：72

A phone screen displays the webpage of Medicare.gov — coverage from STAT — Adobe

Over the past few weeks, Medicare Advantage insurers demanded that the Biden administration give them higher payment rates for next year. The government’s data on how much people were using health care didn’t match their own data, insurers and lobbyists griped — and therefore they wouldn’t be paid enough to cover those costs.

But the federal government was not persuaded by the industry’s data or lobbying push. The Biden administration and its Medicare agency decided to stick with their proposals from January on Monday, dealing a blow to an insurance industry that has come to rely on Medicare Advantage for a steady stream of profits.

The result: In 2025, right after a new president is elected, Medicare Advantage insurers will have to absorb a slight decrease of 0.2% to the baseline payment rates that insurers receive from the government for enrolling older adults and people with disabilities. The stock prices of the largest Medicare Advantage insurers — UnitedHealth, Humana, CVS Health, and Elevance Health — all fell by at least 4% in after-hours trading.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Organ aging and disease risk measured by new blood test

WSS

CDC director unscathed in first congressional testimony

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

At ASCO, AstraZeneca reports strong data for breast cancer drug

ReNAgade cuts staff seven months after raising $300 million

ASCO: Palliative care found as helpful given virtually as in person

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

focus

Wikipedia

explore

Hollywood unions extend contract negotiations for actors

Cigna, Humana reportedly in talks to merge

United colonoscopy coverage change 'may cost lives,' doctors say

ReNAgade cuts staff seven months after raising $300 million

Jerome Adams on the need for new antivirals for Covid

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Medical records are filled with copy

Cigna, Humana reportedly in talks to merge

How to save PrEP access — and even expand it

Will the market for weight loss drugs really reach $100 billion?

Wikipedia

BIO selects John Crowley as new CEO

J&J to emphasize cancer drugs, stop much of its vaccine research

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Takeda, Janssen join wearable maker to measure scratching

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

BIO selects John Crowley as new CEO

hotspot

hotspot

hotspot

focus